US approves China-invented painkiller that could reduce fentanyl overdoses
The US Food and Drug Administration (FDA) has approved the first China-invented painkiller designed as a non-opioid alternative, giving it the potential to curb
fentanyl-related overdose deaths.
Qamzova, developed by Nanjing-based biotech firm Delova, is the world's first long-acting injectable analgesic – offering 24-hour pain relief through a single daily injection and marking a milestone for China's growing pharmaceutical industry.
The non-steroidal anti-inflammatory (NSAID) medication belongs to the same group of painkillers as aspirin and ibuprofen. It contains a high concentration of meloxicam, a compound commonly used to reduce pain and inflammation.
According to
Sino Biopharmaceutical , the Chinese conglomerate that owns the commercial rights to Qamzova, clinical trials showed it was effective in reducing post-surgical reliance on opioids.
By providing a safer, long-acting treatment for moderate-to-severe pain, Qamzova directly addresses the US overdose epidemic fuelled by addictive opioids, including fentanyl – a synthetic drug linked to tens of thousands of deaths annually.
Qamzova's arrival underscores China's rising role in innovative medicines development while offering healthcare professionals a critical tool to mitigate opioid dependency risks and improve patient recovery.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
South China Morning Post
13 hours ago
- South China Morning Post
Women's longevity, heart health, workplace wellness and more in focus at Hong Kong summit
A woman enters an emergency room with a sore arm and jaw pain. She fears she is having a heart attack – women are more likely to experience jaw pain as a warning sign. Her mother and grandmother both suffered one, so her concerns are valid. But instead of being tested for one, a doctor tells her she is too anxious and needs to calm down. Having symptoms dismissed, misdiagnosed or ignored, often with devastating consequences, is a scene played out all too often for women, says Dr Marjorie Jenkins, a US doctor specialising in sex- and gender-based medicine. A poster for Women's Health in Focus: A Global Summit. Photo: Amara Communications Taking place at the Asia Society Hong Kong Centre, the summit brings together more than 40 global leaders from healthcare, technology, investment and entrepreneurship. The summit aims to inform attendees about the latest medical breakthroughs in women's health, cutting-edge preventive healthcare and early diagnostics, and women-specific longevity solutions.
South China Morning Post
15 hours ago
- South China Morning Post
Colon cancer survival soars with regular exercise, shows study that ‘astounded' experts
A three-year exercise programme improved survival in colon cancer patients and kept the disease at bay, a first-of-its-kind international experiment showed. With the benefits of the programme rivalling some drugs, experts said cancer centres and insurance plans should consider making exercise coaching a new standard of care for colon cancer survivors. Until then, patients can increase their physical activity after treatment, knowing they are doing their part to prevent cancer from coming back. 'It's an extremely exciting study,' said Dr Jeffrey Meyerhardt of the Dana-Farber Cancer Institute in Boston, in the United States, who was not involved in the research. Exercise programmes can be offered for several thousand dollars per patient, one expert said – 'a remarkably affordable intervention'. Photo: Shutterstock It is the first randomised controlled trial to show a reduction in cancer recurrences and improved survival linked to exercise, Meyerhardt said.
South China Morning Post
19 hours ago
- South China Morning Post
Hong Kong medical device maker to build China plant as US, EU raise trade barriers
Vincent Medical Holdings, a Hong Kong-based medical device maker, has doubled down on manufacturing in China by investing in automation and digitalisation, instead of moving operations abroad amid rising trade barriers in the US and Europe. The maker of disposable radiology products and respiratory devices is building a factory in Kaiping in the western part of the Greater Bay Area, CEO Raymond Choi Cheung-tai said in an interview. Trial operations could start before the end of the year, he added. 'We are transforming into a new business model that will give us the flexibility to set up operations in multiple markets to get around the trade barriers,' said Choi, an industrial engineer by training. 'Our new factory will be nearly fully automated, except for some equipment that requires maintenance by technicians.' The firm has a plant in Dongguan in the southern province of Guangdong, which produces 70 million imaging and respiratory consumables and 100,000 hospital electronic respiratory devices annually. The first phase of the new facility was expected to cost HK$200 million (US$25.5 million), it said. Dongguan is one of the nine cities in the province, which together with Hong Kong and Macau, make up the Greater Bay Area - Beijing's vision for a manufacturing and technology powerhouse to drive the nation's economy. Choi joined Vincent Medical in 2020. He is the son of founder and chairman Choi Man-sing, who controls about 60 per cent of the firm. Sales of disposable imaging products grew 38 per cent to HK$393 million last year, or 49 per cent of the group's revenue. The US and Europe contributed almost 40 per cent each to its sales.
